AVITA Medical (RCEL) Cash from Financing Activities (2019 - 2025)
AVITA Medical (RCEL) posted Cash from Financing Activities of $248000.0 for Q4 2025, down 98.2% on a QoQ basis from $13.8 million in Q3 2025, and down 75.71% year-over-year from $1.0 million in Q4 2024.
AVITA Medical (RCEL) Cash from Financing Activities (2019 - 2025) Analysis & Trends
AVITA Medical's Cash from Financing Activities history runs 7 years deep, the most recent figure standing at $248000.0 for Q4 2025.
- Quarterly Cash from Financing Activities fell 75.71% year-over-year to $248000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $14.9 million (up 325.77% YoY) and the FY2025 annual result came in at $14.9 million, up 325.77% from the prior year.
- Cash from Financing Activities was $248000.0 for Q4 2025 at AVITA Medical, down from $13.8 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $64.1 million in Q3 2021 and bottomed at -$64.1 million in Q4 2022.
- A 5-year average of $2.6 million and a median of $579500.0 in 2023 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2021 — Cash from Financing Activities soared 1601625.0% — and 2022, when it plunged 397.95%.
- AVITA Medical's Cash from Financing Activities stood at $64.1 million in 2021, then plunged by 200.0% to -$64.1 million in 2022, then surged by 161.55% to $39.4 million in 2023, then plunged by 97.41% to $1.0 million in 2024, then tumbled by 75.71% to $248000.0 in 2025.
- Business Quant data shows RCEL's Cash from Financing Activities at $248000.0 in Q4 2025, $13.8 million in Q3 2025, and $559000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 17.31 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | -1.51 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -260.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -451.20 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | -25.00 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -26.93 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 21.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | AVITA Medical | 140.94 Mn | 124.59 Mn | 14.31 Mn | 248,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 248,000.00 |
| Dec 31, 2025 | 248,000.00 |
| Sep 30, 2025 | 13.77 Mn |
| Sep 30, 2025 | 13.77 Mn |
| Jun 30, 2025 | 559,000.00 |
| Jun 30, 2025 | 559,000.00 |
| Mar 31, 2025 | 363,000.00 |
| Mar 31, 2025 | 363,000.00 |
| Dec 31, 2024 | 1.02 Mn |
| Dec 31, 2024 | 1.02 Mn |
| Sep 30, 2024 | 1.01 Mn |
| Sep 30, 2024 | 1.01 Mn |
| Jun 30, 2024 | 849,000.00 |
| Jun 30, 2024 | 849,000.00 |
| Mar 31, 2024 | 631,000.00 |
| Mar 31, 2024 | 631,000.00 |
| Dec 31, 2023 | 39.43 Mn |
| Dec 31, 2023 | 39.43 Mn |
| Sep 30, 2023 | 600,000.00 |
| Sep 30, 2023 | 600,000.00 |